PBM Formulary Restrictions vs. Pharmacy Liens: Access Guide

James Wong — Founder & CEO, LienScripts | March 29, 2026 | 8 min read

Pharmacy Benefit Manager (PBM) formulary restrictions frequently block PI patients from accessing clinically appropriate medications. Pharmacy liens bypass PBM gatekeeping, ensuring patients receive the medications their treating physicians prescribe without formulary limitations.

PBM Formulary Restrictions vs. Pharmacy Liens: When PBMs Block Access, Liens Provide It

Pharmacy Benefit Managers (PBMs) control medication access through formulary restrictions, prior authorization requirements, step therapy protocols, and quantity limits that frequently prevent personal injury patients from receiving the medications their treating physicians prescribe. A pharmacy lien bypasses these PBM restrictions entirely, ensuring that clinically appropriate medications reach injured patients without insurance gatekeeping.

• PBM formulary restrictions block access to medications that treating physicians determine are clinically necessary for accident-related injuries
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages
• Pharmacy liens eliminate prior authorization delays, step therapy requirements, and formulary exclusions that PBMs impose on accident-related prescriptions
• According to James Wong, PharmD, founder of LienScripts, PBM restrictions are designed for population-level cost management and often fail to account for the acute, injury-specific medication needs of PI patients
• The medications blocked by PBMs but provided through pharmacy liens document the gap between insurance-covered care and the treatment the injury actually required

How PBMs Restrict Medication Access

Formulary Exclusions

PBMs maintain formularies — lists of covered medications — that exclude many drugs used in PI treatment. Brand-name medications without generic equivalents (Qulipta for post-traumatic migraine, Journavx for acute pain) are frequently excluded entirely. Patients with PBM-managed insurance who need these medications face a binary choice: pay full price out of pocket or go without.

Prior Authorization

Prior authorization requires the prescribing physician to submit clinical documentation to the PBM before the medication can be dispensed. The PBM reviews the documentation and either approves or denies coverage. This process typically takes 3-7 business days but can extend to weeks with appeals.

For a PI patient in acute pain, a one-week prior authorization delay is medically unacceptable. The patient suffers while waiting for an insurance bureaucracy to approve a treatment decision already made by a licensed physician.

[!KEY] Prior authorization delays create documented treatment gaps that adjusters later use to argue the injury was not severe. A pharmacy lien eliminates this delay entirely — the medication is dispensed as soon as the physician prescribes it, creating a continuous treatment timeline that supports the demand package.

Step Therapy (Fail-First Protocols)

Step therapy requires patients to try cheaper medications first and fail on them before the PBM will cover the physician's preferred medication. A patient prescribed pregabalin for neuropathic pain may be required to try gabapentin first, fail on it, and document that failure before the PBM authorizes pregabalin coverage.

For PI patients, step therapy imposes weeks or months of suboptimal treatment. The treating physician, who has examined the patient and determined that pregabalin is the appropriate medication, is overruled by a PBM algorithm designed for cost management.

Quantity Limits

PBMs impose quantity limits that may restrict the number of tablets, capsules, or doses a patient can receive per fill period. A pain management patient who requires medication three times daily may be limited to a quantity that allows only twice-daily dosing, creating periods of untreated pain.

How Pharmacy Liens Bypass PBM Restrictions

A pharmacy lien operates outside the insurance payment system entirely. The medication is dispensed on lien — meaning payment is deferred until case settlement — without involving the patient's health insurance or its PBM.

No formulary restrictions. Any medication prescribed by the treating physician can be dispensed on lien, regardless of whether the PBM covers it.

No prior authorization. The prescription is filled when received. No PBM approval is needed because the PBM is not involved in the transaction.

No step therapy. The treating physician's first-choice medication is dispensed immediately. The patient does not need to fail on cheaper alternatives first.

No quantity limits. The prescribed quantity is dispensed as written, without PBM-imposed restrictions.

[!TIP] When a patient's PBM denies or restricts a medication that the treating physician has prescribed for accident-related injuries, the prior authorization denial letter itself becomes powerful evidence. Include it in the demand package to document that the patient's insurance system failed to provide adequate care, necessitating the pharmacy lien.

The Evidentiary Value of PBM-Bypassed Medications

Documenting the Care Gap

Medications dispensed through a pharmacy lien that would not have been covered by the patient's PBM document a care gap — the difference between what insurance would have provided and what the injury actually required. This gap is directly relevant to damages.

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "When a PBM excludes a CGRP antagonist for post-traumatic migraine and the patient receives it on lien, the demand package can show precisely what the insurance system failed to provide. The lien-dispensed medication proves the injury required treatment that exceeded what the patient's insurance would cover."

Supporting Brand-Name Medication Choices

PBMs push generic substitution regardless of clinical circumstances. When a treating physician prescribes a brand medication for a specific clinical reason — different mechanism of action, better side effect profile for this patient, no true generic equivalent — the PBM may substitute or deny coverage.

The pharmacy lien allows the physician's clinical judgment to prevail over PBM cost management. The demand package shows that the treating physician prescribed a specific medication for documented clinical reasons, and the pharmacy lien ensured the patient received it.

Continuous Treatment Timeline

PBM-caused delays (prior authorization processing, step therapy trials, appeal periods) create interruptions in the treatment timeline. These interruptions appear as gaps in the pharmacy record that adjusters exploit.

A pharmacy lien produces a continuous treatment timeline from the first prescription forward. This unbroken record supports the narrative that the patient was promptly and continuously treated for accident-related injuries.

Common PBM-Blocked Medications in PI Cases

CGRP antagonists (Qulipta, Nurtec, Ubrelvy): Frequently excluded from PBM formularies or subject to stringent prior authorization. These are first-line treatments for post-traumatic migraine.

Nav1.8 inhibitors (Journavx): New non-opioid pain medications often face formulary exclusion or extensive prior authorization requirements.

Compound medications: PBMs generally do not cover compounded formulations (topical pain creams, customized capsules), even when the treating physician determines that a commercially available product is not appropriate.

Brand-specific formulations: Extended-release, delayed-release, or specialized formulations of medications that have generic immediate-release versions (Celebrex vs. generic celecoxib, Skelaxin vs. generic metaxalone) face PBM substitution mandates.

[!KEY] The LienScripts MERIT report documents which medications on the lien would not have been accessible through the patient's insurance due to PBM restrictions, creating a clear record of the care gap that the pharmacy lien filled. This documentation directly supports the necessity of the lien and the reasonableness of lien-based dispensing.

PBM Restrictions as a Settlement Argument

The existence of PBM restrictions supports the pharmacy lien in settlement negotiations in two ways:

1. Necessity of the lien. The patient needed the pharmacy lien because their insurance could not or would not provide the prescribed medications. The lien was not a choice to avoid insurance — it was a necessity created by PBM restrictions.

2. Treatment quality. The medications dispensed on lien represent the treating physician's clinical judgment, unconstrained by PBM cost management. The patient received the treatment their injury required, not the cheaper treatment their insurance allowed.

Contact LienScripts to learn how pharmacy liens provide medication access when PBM restrictions block treatment.

Related Resources

• Insurance Denial and Medication Access Through Pharmacy Liens
• Step Therapy Fail-First Bypass With Pharmacy Liens
• Pharmacy Services for Personal Injury Clients: How It Works